Applied Therapeutics ( (APLT) ) has released its Q3 earnings. Here is a breakdown of the information Applied Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare metabolic diseases and diabetic complications. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting its financial performance and strategic developments. Key financial metrics from the report indicate a net loss of $18.99 million for the quarter, with total revenue of $1 million, primarily from license revenue. The company also reported a decrease in cash and cash equivalents to $11.9 million, down from $79.4 million at the end of 2024. Despite the financial challenges, Applied Therapeutics continues to focus on advancing its product candidates and exploring potential long-term financing options. Looking ahead, the company remains committed to its strategic goals and is actively pursuing partnerships and additional funding to support its operations and development programs.